What is Mounjaro?

What is Mounjaro?

Mounjaro is a relatively new medication that is increasingly being discussed in the context of weight management. This drug combines two mechanisms of action that together enable more effective weight management than previously available treatments. This article explains exactly what Mounjaro is, what it is used for, who it is intended for, and what role Goodweight plays if you want to find out if this treatment path is right for you.

What is the active ingredient in Mounjaro?

The active ingredient in Mounjaro is tirzepatide. It is a "dual agonist": it simultaneously activates two hormone receptors in the body, namely the GLP-1 receptor and the GIP receptor. GLP-1 is a hormone that stimulates insulin production, inhibits the release of glucagon, and slows gastric emptying, which helps maintain a feeling of fullness for longer. GIP has a complementary effect on glucose metabolism and adipose tissue metabolism. Because tirzepatide activates these two receptors simultaneously, its effect on satiety and weight is more significant than that of medications that act solely on GLP-1.

What is Mounjaro used for?

Mounjaro was originally developed for the treatment of type 2 diabetes. This medication helps regulate blood sugar by increasing insulin production and inhibiting the release of glucagon based on current blood sugar levels. Its safety and efficacy have been proven. Because patients in clinical trials also experienced significant weight loss, tirzepatide was later studied as a treatment for obesity in non-diabetics. The European Medicines Agency (EMA) has since granted marketing authorization for the drug for weight management in adults with a BMI of ≥ 30, or a BMI of ≥ 27 with a weight-related health condition.

How does Mounjaro promote weight loss?

Mounjaro promotes weight loss by acting on several mechanisms simultaneously. It slows gastric emptying, which prolongs the feeling of fullness after a meal. It also affects areas of the brain that regulate appetite, thereby reducing the urge to eat. At the same time, the effect of GIP influences fat storage and burning. The combined effect of GLP-1 and GIP explains the stronger effect on weight loss compared to previous treatments. As shown by the phase III SURMOUNT-1 study, participants who received Mounjaro lost an average of 15–22% of their body weight after 72 weeks, and about half of them lost more than 20% at the highest dose.

Is Mounjaro already available in the Netherlands?

Mounjaro is available in the Netherlands through approved healthcare providers. The drug has received EMA approval, and doctors can prescribe it for the treatment of obesity. However, its availability is currently limited; supply may vary from pharmacy to pharmacy and by region. If you are considering using Mounjaro, it is recommended to consult with a healthcare professional first. Where to buy Mounjaro and how to do so safely depends on your personal situation and a preliminary assessment.

What is the difference compared to other weight loss medications?

The biggest difference between Mounjaro and other weight loss medications is its mechanism of action. Medications such as semaglutide (the active ingredient in Ozempic and Wegovy) are pure GLP-1 agonists. Tirzepatide additionally activates GIP. Compared to semaglutide, tirzepatide leads to greater weight loss, as several clinical studies have shown. A systematic analysis of all available clinical trials has further demonstratedthat tirzepatide is consistently more effective than most other available options. More information on the differences between Mounjaro and Ozempic can be found in our blog article, which compares aspects such as side effects and dosage instructions. If you would also like to learn more about alternatives to Ozempic, Goodweigh provides a detailed comparison.

Who is Mounjaro for?

Mounjaro is intended for adults aged 18–75 with a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition such as high blood pressure, sleep apnea, or prediabetes. This medication is not suitable for individuals with a history of pancreatitis, medullary thyroid carcinoma, or MEN2 syndrome, nor for women who are pregnant or breastfeeding. Your eligibility for GLP-1 treatment depends on several factors that a doctor will evaluate with you.

Is it safe to use Mounjaro?

The EMA has approved Mounjaro following a thorough clinical assessment, and it is considered safe when used for its approved indications and as directed. The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and loss of appetite, particularly at the start of treatment and when increasing the dose. These side effects usually subside as your body adjusts to the medication. Serious side effects, such as acute pancreatitis or gallstones, are rare but require immediate medical attention. Always use this medication under medical supervision and report any side effects to your treating physician.

What does Goodweigh offer in relation to Mounjaro?

Goodweigh offers a medically supervised weight management program where tirzepatide can be used as part of an individualized treatment plan. This means a doctor will assess your situation, determine if Mounjaro is right for you, create an appropriate dosage schedule, and support you throughout the process. The weight loss achievable with Mounjaro depends on personal factors, but with the medical support provided by Goodweigh , you can progress systematically toward sustainable results.

Would you like to know more about Mounjaro? Start with an initial consultation at Goodweigh

Mounjaro is an effective and scientifically proven treatment for individuals seeking medical support for weight loss. Its suitability for your specific situation depends on your health status, weight, and treatment goals. Goodweigh will help you gain clarity on the matter an initial medical consultation so that you can make an informed decision.